Currently used AD treatments include the acetylcholinesterase inhibitor donepezil, which regulates learning/memory, neuroinflammation, and Aβ pathology in AD patients [5–7], but the impact of donepezil on tau phosphorylation has received limited attention. This evidence concerns the gene MAPT and Alzheimer disease.